SCHEMBL1865178

SCHEMBL1865178

CSc1cccc(OC(C)=O)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
CYP3A4 P08684 1/20 0.59
ACHE P22303 2/20 0.54
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
TP53 P04637 3/20 0.46
ALDH1A1 P00352 2/20 0.46
RAB9A P51151 2/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 1/20 0.43
HTT P42858 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29609451 0.87 LMNA (0.61) LMNACYP3A4ACHEMEN1KMT2A
SCHEMBL249305 0.82 LMNA (0.76) LMNACYP3A4ACHEMEN1KMT2A
SCHEMBL17028900 0.82 LMNA (0.76) LMNACYP3A4ACHEMEN1KMT2A
SCHEMBL4978773 0.80 LMNA (0.53) LMNACYP3A4ACHEMEN1KMT2A
SCHEMBL13049316 0.78 LMNA (0.60) LMNACYP3A4ACHEMEN1KMT2A
Ethylene SCHEMBL28866733 0.78 LMNA (0.70) LMNACYP3A4ACHEMEN1KMT2A
SCHEMBL5736094 0.77 CYP3A4 (0.54) LMNACYP3A4ACHEMEN1KMT2A
SCHEMBL20350297 0.77 SMN1; SMN2 (0.44) LMNAMEN1KMT2ASMN1; SMN2TP53
SCHEMBL16952895 0.77 LMNA (0.63) LMNACYP3A4ACHEMEN1KMT2A
SCHEMBL16960697 0.76 LMNA (0.38) LMNACYP3A4ACHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935699-B2 Pyrazole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-03 US disclosed
EP-2261216-A2 Pyrazoles as glucokinase activators F. Hoffmann-La Roche AG (CH) 2010-12-15 EP disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 US disclosed
CN-1976907-A Heterocyclic amide compound and use thereof as an MMP-13 inhibitor TAKEDA PHARMACEUTICAL (JP) 2007-06-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 LMNA 4599/4885CYP3A4 531/4885ACHE 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.